Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term open-label safety and efficacy study of ACZ885 (canakinumab) in CAPS patients
2007-004367-22Phase 3Completed
- Sponsor
- Novartis
- Start
- Mar 2008
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of canakinumab in cryopyrin-associated periodic syndrome (CAPS), familial cold autoinflammatory syndrome (FCAS), Muckle-Wells syndrome (MWS), neonatal-onset multisystem inflammatory disease (NOMID), sponsored by Novartis. Started Mar 2008; status: completed.
02
Drugs
canakinumab
03
Conditions
cryopyrin-associated periodic syndrome (CAPS)familial cold autoinflammatory syndrome (FCAS)Muckle-Wells syndrome (MWS)neonatal-onset multisystem inflammatory disease (NOMID)
Beyond the preview
Go deeper on 2007-004367-22.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-004367-22.